Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant by Merkel, Melissa et al.
1755
Hepatology CommuniCations, Vol. 5, no. 10, 2021  
Protective Effects of Statin Therapy in 
Cirrhosis Are Limited by a Common 
SLCO1B1 Transporter Variant
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Matthias C. Reichert 1
Complications of cirrhosis and portal hypertension (PH) can be reduced by statin therapy. The common loss- of- 
function variant p.V174A in the solute carrier organic anion transporter gene 1B1 (SLCO1B1) gene encoding the 
organic anion transporting polypeptide 1B1 results in decreased hepatic uptake of statins. Our specific aim was to 
assess the impact of this variant in patients with cirrhosis and statin treatment while controlling for the stage of cir-
rhosis and other potential confounders with propensity score matching (PSM), availing of a large cohort of genotyped 
study patients. In total, from 1,088 patients with cirrhosis in two German academic medical centers, PSM yielded 
154 patients taking statins and 154 matched controls. The effect on PH was assessed by the liver stiffness– spleen 
size– to– platelet score (LSPS), and complications of cirrhosis were retrospectively recorded applying consensus criteria. 
As hypothesized, patients on statin treatment presented less frequently with signs of PH: Esophageal varices (41% 
vs. 62%; P  <  0.001) were less common, and LSPS (4.8  ±  11.5 vs. 5.6  ±  6.4; P  =  0.01) was reduced. Correspondingly, 
decompensation events were also reduced in patients on statins (odds ratio [OR]  =  0.54, 95% confidence interval [CI] 
0.32- 0.90; P  =  0.02). When the variant in SLCO1B1 was present in patients on statins, esophageal varices (OR  =  2.68, 
95% CI 1.24- 5.81; P  =  0.01) and bacterial infections (OR  =  2.50, 95% CI 1.14- 5.47; P  =  0.02) were more common as 
compared with wild type carriers on statins. Conclusion: In this cohort, signs and complications of PH were reduced in 
patients with cirrhosis treated with statins. Notably, this effect was diminished by the common loss- of- function vari-
ant in SLCO1B1. Further prospective studies in independent cohorts are warranted to confirm these genotype- specific 
observations. (Hepatology Communications 2021;5:1755-1766).
Cirrhosis, the common end stage of chronic liver diseases, is caused by destruction and remodeling of hepatic tissue. Starting with a 
compensated status, the disease can further develop 
into the decompensated stage, which is characterized 
by markedly elevated mortality with median survival 
of 2  years, as compared with more than 12  years 
in the compensated stage.(1) Decompensation is 
defined by the development of ascites, variceal 
bleeding, hepatic encephalopathy (HE), or hepato-
renal syndrome (HRS). Portal hypertension (PH) is 
an important factor for the development of decom-
pensation and the clinical course in patients with 
cirrhosis.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, conf idence interval; CK, creatine kinase; EHR, electronic 
health records; FIB- 4, Fibrosis- 4 index; HDL, high- density lipoprotein; HE, hepatic encephalopathy; HRS, hepatorenal syndrome; INR, international 
normalized ratio; LDL, low- density lipoprotein; LSM, liver stiffness measurement; LSPS, liver stiffness– spleen size– to– platelet score; MELD, model 
of end- stage liver disease; OR, odds ratio; PH, portal hypertension; PSM, propensity score matching; SLCO, solute carrier organic anion transporter.
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Data from both experimental and human studies con-
sistently confirm that 3- hydroxy- 3- methylglutaryl- CoA 
reductase inhibitors, also known as statins, lower PH 
and are associated with reduced mortality.(2) A pro-
spective placebo- controlled hemodynamic study in 
humans reported that 1  month of simvastatin treat-
ment (40 mg/day) lowers the hepatic venous pressure 
gradient by 8%.(3) This reduction of portal pressure 
could also be observed in preclinical models and 
prospective controlled studies.(4- 6) A randomized 
controlled trial evaluated a 2- year therapy with sim-
vastatin in the setting of secondary variceal bleeding 
prophylaxis. In this setting, a reduced mortality was 
observed in patients on simvastatin.(7) Several retro-
spective studies reported an impact of statin therapy 
on decompensation events, infections, and mortality(8) 
in patients with cirrhosis.(8,9)
These beneficial effects of statins are not uniform in 
all patients. The variability of the effects may be due to 
different drug concentrations resulting from variants of 
enzymes and/or transporters involved in statin metab-
olism. Statin- induced myopathy as a frequent side 
effect of statin treatment(10) has been suggested to be 
mediated by increased statin plasma concentrations. In 
a landmark genome- wide association study, the com-
mon single nucleotide variant c.521T>C in the solute 
carrier organic anion transporter gene 1B1 (SLCO1B1) 
has been associated with statin- induced myopathy,(11) 
a finding that has been validated in several follow- up 
studies.(12) This gene encodes the organic anion trans-
porting polypeptide 1B1, which is localized in the 
sinusoidal membrane of hepatocytes and mediates 
the hepatic uptake of various metabolites, including 
unconjugated bilirubin and xenobiotics such as statins 
or methotrexate.(13) Among the variants associated 
with an impaired transporter function,(14) c.521T>C, 
which results in the amino acid substitution p.V174A 
and loss of function, decreases the reduction of low- 
density lipoprotein (LDL) cholesterol concentrations 
by simvastatin significantly.(11) Patients on statins car-
rying this common SLCO1B1 variant exhibit a 3- fold 
elevated area under the curve of simvastatin metabo-
lite levels in plasma.(15) These effects have also been 
reported for other statins(16) and are mediated by 
reduced intrahepatic statin concentrations.(17)
The aim of this study was to evaluate the effect 
of statin treatment on PH and other complications 
of cirrhosis, and to consecutively assess whether the 
common SLCO1B1 loss- of- function variant p.V174A 
impacts the effects of statin treatment in patients with 
cirrhosis. To conduct this analysis, propensity score 
matching (PSM) within a large retrospectively char-
acterized study cohort was chosen, which provides a 
sufficient number of patients carrying the risk variant 
for successful matching.
Patients and Methods
Overall, 1,088 patients with cirrhosis and genetic 
data on the SLCO1B1 variant p.V174A were retrospec-
tively included from two German academic medical 
centers in Halle and Homburg between April 2013 and 
April 2019 in the context of screening for the random-
ized controlled INCA (Impact of NOD2 genotype– 
guided antibiotic prevention on survival in patients 
with liver Cirrhosis and Ascites) trial.(18) Patients with-
out confirmed diagnosis of cirrhosis and missing infor-
mation about statin medication were excluded. Patients 
with severe comorbidities such as chronic heart fail-
ure (ejection fraction <20%), or nonresectable cancers 
except limited hepatocellular carcinoma (Barcelona 
Clinic Liver Cancer stages A- C) were excluded. The 
study was conducted according to the Declaration of 
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Helsinki and the Good Clinical Practice guidelines of 
the European Medicines Agency. Institutional review 
board approval was obtained (Homburg #271/11, 
Halle #2017- 85), and all participants provided written, 
informed consent. Electronic health records (EHRs) 
were retrospectively reviewed at the index date with 
uniform criteria, including all necessary information 
on diagnosis and stage of cirrhosis as well as decom-
pensation events, as outlined subsequently (Fig. 1). 
Information from previous events of decompensations 
at other centers were questioned and considered. The 
index date was the inclusion in the analysis. To allow us 
to include as much data as possible, this provided data 
for different stages of cirrhosis. Laboratory parameters 
were compared as absolute values.
Diagnosis oF CiRRHosis
Cirrhosis was defined by (1) biopsy, (2) a combina-
tion of clinical (jaundice, liver skin signs), laboratory 
(parameters of parenchymal damage and synthesis 
performance), ultrasound (ascites, narrow intrahepatic 
vessels, rounded edges, heterogeneous parenchyma, 
enlarged or small liver, enlarged caudate lobe, collat-
erals, and/or liver surface nodularity), and endoscopic 
examinations (presence of varices and signs of PH), 
or (3) liver stiffness measurement (LSM) > 13.0 kPa. 
In patients with LSM < 19.7 kPa,(19) diagnosis of cir-
rhosis was additionally confirmed by (1) or (2). EHRs 
were retrospectively reviewed for clinical data, includ-
ing clinical decompensation before and at index date. 
Further information regarding medication use and 
laboratory parameters at the time of inclusion were 
also recorded.
statin eXposition
Statin exposition was assessed retrospectively for 
all patients with a statin prescription at the index date 
based on EHR entries. Changes in medication were 
documented at all contacts in the department, both for 
inpatients and outpatients. Exact data on beginning 
of the statin exposure were not available for the full 
cohort. Patients receiving the first prescription at index 
date were considered as not exposed (n  =  3, 1.8%). 
To compare different kinds of statins with variable 
potency, we calculated the simvastatin equivalent dose 
and additionally derived the effects on LDL choles-
terol concentrations, defining three intensity groups.(20) 
Statin- induced myopathy was assessed by analyzing the 
EHR. Statin- induced myopathy was defined as change 
or discontinuation of statin therapy in the case of ele-
vated creatine kinase (CK) activities (male > 174 U/L, 
female > 140 U/L) and/or clinical signs of myopathy.
Fig. 1. Flow chart outlining the inclusion and exclusion of the patients for the PSM analysis. Abbreviations: HCC, hepatocellular 
carcinoma; HIV, human immunodeficiency virus.
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DeCompensation oF CiRRHosis
Decompensation was defined as the presence of 
ascites, HE, HRS, jaundice, and/or variceal bleed-
ing. Diagnostic criteria correspond to the European 
Association for the Study of the Liver guidelines.(21) 
The presence of ascites was confirmed by physi-
cal examination and/or by abdominal sonography. 
Patients without clinical signs of ascites who took 
diuretics (e.g., spironolactone) were considered to 
have ascites. HE was assessed by the West Haven cri-
teria.(22) Criteria for HRS were applied as currently 
recommended.(21) Jaundice was arbitrarily defined 
by a total bilirubin ≥3 mg/dL, or a bilirubin increase 
of ≥3  mg/dL from previous concentrations. Variceal 
bleeding was defined as hematemesis or melena lead-
ing to hospitalization and diagnosed by a physician 
and endoscopy.
BaCteRial inFeCtions
All episodes of previous or current bacterial infec-
tions, which took place after the diagnosis of cirrho-
sis, were recorded. Bacterial infections were defined 
according to the criteria outlined by Bajaj et al.(23) 
Inclusion criterion was treatment with antibiotics.
tRansient elastogRapHy anD 
otHeR noninVasiVe maRKeRs
Transient elastography is an ultrasound- based 
noninvasive method with high accuracy to diagnose 
liver fibrosis, cirrhosis,(19) and PH.(24) Recent reports 
demonstrate that it is able to predict esophageal var-
ices.(25) LSM with interquartile range ≤30% and suc-
cess rate >60% were considered as reliable.(25)
Liver stiffness– spleen size– to– platelet score (LSPS) 
is an established noninvasive marker to assess clini-
cally significant PH and esophageal varices.(24,26) The 
parameters composing LSPS are common, easy to 
access, and thus available for patients with cirrhosis 
who undergo LSM using elastography. To determine 
spleen size, the diameter crossing the hilus was mea-
sured in ultrasound or cross- sectional imaging (com-
puted tomography or magnetic resonance imaging). 
Data closest to inclusion date were selected (maxi-
mum interval of 14 days).
The Fibrosis- 4 (FIB- 4) index was calculated as fol-
lows: age [years] × aspartate aminotransferase [AST; 
IU/L]/(platelet count × 109/L) × ALT [alanine amino-
transferase; IU/L]. The ratio is a noninvasive marker 
for detecting advanced hepatic fibrosis.(27) In compen-
sated cirrhosis, the score identifies patients with clini-
cally significant PH and esophageal varices.(28)
genotyping
Isolation of genomic DNA from ethylenedi-
aminetetraacetic acid- anticoagulated blood was per-
formed using a membrane- based extraction kit (Qiagen, 
Hilden, Germany). The SLCO1B1 polymorphism 
rs4149056 (c.521T>C, p.V174A), which is in nearly 
complete linkage disequilibrium with rs4363657,(11) 
was genotyped using TaqMan polymerase chain reac-
tion (assay C_30633906_10). The genotype distribu-
tions were compared with data stored in the gnomAD 
browser (https://gnomad.broad insti tute.org).(29)
statistiCal analysis
To minimize structural differences between patients 
on statins and patients without statins, such as differ-
ent metabolic status, compliance, and cirrhosis devel-
opment, PSM was applied. Propensity scores were set 
up to adjust for 19 confounders (Table 1). Most con-
founders are associated with the stage of liver disease. 
With respect to the application of PSM, we excluded all 
patients with missing data in matching variables. These 
patients represent only 3% of the collective and were 
excluded, as they could not be characterized because 
of lack of information. Hence, 979 patients underwent 
initial PSM. Selection of the parameters was based on 
a potential impact on the success of statin therapy and 
not on exposition to statins.(30) Propensity scores were 
matched 1:1 with a greedy matching algorithm, apply-
ing nearest- neighbor matching with a caliper of 0.15. 
In total, 154 statin- treated patients could be matched 
to 154 nonstatin users. Twelve statin users could not 
be matched and were excluded. PSM and subse-
quent analyses were performed with the “psmatching” 
module in SPSS v24.0 (IBM, Munich, Germany) 
under R- Plugin v3.2.5 and R- Essentials for SPSS. 
To compare the matched groups, conditional logistic 
regression models, t tests for two related samples, or 
Wilcoxon rank tests, depending on the distributions 
of the test variables, were used. Hardy- Weinberg equi-
librium was tested with an exact test (https://ihg.gsf.
de/cgi- bin/hw/hwa2.pl). Genetic subgroup analysis 
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was conducted applying χ2 tests for contingency tables, 
t tests, or Mann- Whitney U tests. Two- sided P val-
ues  <  0.05 were regarded as significant. All variables 
are described as proportions or means with SD.
Results
patient CHaRaCteRistiCs anD 
matCHing
After exclusion and matching, we studied 308 
patients in total (154 patients on statins and 154 
nonstatin users) (Fig. 1). The median age of these 
patients was 65.3 ± 9.8 years, and 76.9% of the patients 
(n = 237) were men (Table 2). The most common eti-
ology of cirrhosis in our cohort was alcohol- associated 
liver disease (n  =  144; 46.8%). Child- Turcotte- Pugh 
scores were distributed as follows: 36.4% of patients 
were class A, 30.8% were class B, and 11.3% were 
class C. Mean Model for End- stage Liver Disease 
(MELD) score was 11.9 ± 4.8, and mean LSPS was 
5.2 ± 9.4.
Table 1 summarizes the matching variables before 
and after matching. Before PSM, patients on statins 
were (1) younger and primarily male with (2) lower 













Age (years) 59.7 ± 11.2 66.1 ± 9.6 <0.001 65.2 ± 10.3 65.3 ± 9.4 0.75
Sex
Female 296 (36.4) 40 (24.1) 0.002 32 (20.5) 39 (25.3) 0.34
Male 517 (63.6) 126 (75.9) 122 (79.5) 115 (74.7)
Etiology of cirrhosis
Alcoholism 460 (56.6) 70 (42.2) 75 (48.7) 69 (44.8)
Hepatitis B 27 (3.3) 3 (1.8) 4 (2.6) 3 (1.9)
Hepatitis C 118 (14.5) 12 (7.2) 13 (8.4) 12 (7.8)
Metabolic 49 (6.0) 23 (13.9) 12 (7.8) 22 (14.3)
Cryptogenic 69 (8.5) 37 (22.3) 26 (16.9) 29 (18.8)
Other 90 (11.1) 21 (12.6) 24 (15.6) 19 (12.3)
Diabetes 221 (27.2) 88 (53.0) <0.001 77 (50.0) 77 (50.0) 0.90
Medication
β- blocker 383 (47.1) 100 (60.2) 0.002 95 (61.7) 88 (57.1) 0.39
Long- term antibiotic therapy 162 (19.9) 21 (12.7) <0.001 20 (13.0) 21 (13.6) 0.87
Lactulose 331 (40.7) 43 (25.9) 0.03 46 (29.9) 42 (27.3) 0.56
PPI 517 (70.2) 129 (77.7) 0.05 114 (74.0) 118 (76.6) 0.56
Therapy of viral hepatitis 110 (13.5) 10 (6.0) 0.007 10 (6.5) 10 (6.5) 1.00
Bacterial infection 2 weeks before inclusion 126 (15.5) 16 (9.6) 0.05 14 (9.1) 15 (9.7) 0.85
Hospitalization 6 months before inclusion 441 (54.2) 70 (42.2) 0.005 70 (45.5) 69 (44.8) 0.91
Hospitalization ever 716 (88.1) 143 (86.1) 0.49 141 (91.6) 133 (86.4)) 0.16
Treatment in ICU ever 151 (18.6) 39 (23.5) 0.15 35 (22.7) 35 (22.7) 1.00
Laboratory parameters
Serum sodium (mmol/L) 138 ± 5 139 ± 4 0.001 138 ± 4 139 ± 4 0.08
Serum creatinine (mg/dL) 1.1 ± 0.8 1.2 ± 0.7 0.003 1.2 ± 0.8 1.2 ± 0.7 0.86
Total bilirubin (mg/dL) 2.8 ± 4.8 1.5 ± 1.8 <0.001 1.4 ± 1.3 1.5 ± 1.9 0.46
Serum albumin (g/dL) 34.8 ± 7.2 36.3 ± 8.0 0.01 35.5 ± 7.0 36.1 ± 8.3 0.28
Hemoglobin (g/dL) 11.9 ± 2.6 12.6 ± 2.3 0.002 12.3 ± 2.4 12.5 ± 2.4 0.68
INR 1.3 ± 0.4 1.3 ± 0.3 0.01 1.3 ± 0.3 1.3 ± 0.3 0.94
Note: Data are presented as frequency and percentage or means and SD. Significant P values are marked in bold. Decompensated patients 
can have multiple decompensation events.
Abbreviation: ICU, intensive care unit.
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severity of liver disease, as reflected by lower total bil-
irubin concentrations as well as higher serum albu-
min and hemoglobin levels; (3) the prevalence rates 
of alcohol- associated liver disease as well as chronic 
hepatitis B and C infections were lower, whereas met-
abolic and cryptogenic causes of liver disease were 
more than twice as frequent; and (4) as expected, the 
patients on statins were more likely to have diabetes. 
After PSM, all standardized differences of matching 
parameters were reduced, and there was no differ-
ence with respect to comorbidities, as reflected by the 
Charlson indexes in both groups (Table 3).
Among the patients on statins, the most prescribed 
statin was simvastatin (63%, information available for 
138 patients), followed by atorvastatin (28%). The 
mean simvastatin equivalent dose in our cohort was 
35 mg ± 22 mg per day (Table 2).
eFFeCts oF statin tReatment 
on CiRRHosis
Patients with cirrhosis treated with statins were less 
likely to present with events of decompensation (odds 
ratio [OR] = 0.54, 95% confidence interval [CI] 0.32- 
0.90; P = 0.02), primarily due to the significantly lower 
frequency of variceal bleeding (6% vs. 14%; P  =  0.02) 
and ascites (48% vs. 60%; P = 0.04) (Table 3). Indeed, 
corresponding signs of PH such as the endoscopic pres-
ence of esophageal varices (41% vs. 62%; P  <  0.001), 
LSPS (4.8 ± 11.5 vs. 5.6 ± 6.4; P = 0.01), FIB- 4 index 
(4.8  ±  10.1 vs. 5.4  ±  4.7; P  =  0.02), and spleen size 
(13.1 ± 2.5  cm vs. 13.8 ± 2.9  cm; P  = 0.02) were sig-
nificantly reduced in patients on statins. Furthermore, 
platelet counts were significantly higher (182  ±  104 × 
109/L vs. 146 ± 87 × 109/L; P < 0.001) in statin- treated 
patients. On statin treatment, serum lipids (in partic-
ular total, LDL, and high- density lipoprotein [HDL] 
cholesterol concentrations) did not differ from patients 
without statins (Table 3).
Serum CK activities were significantly elevated in 
patients on statins (112 ± 91 IU/L vs. 96 ± 77 IU/L; 
P  =  0.03), which could reflect the myotoxicity of 
statins. In the statin cohort, three cases of statin- 
induced myopathy were observed (1.9%), as compared 
with no cases in the nontreated patients. Serum ALT 
and AST activities did not differ between the groups 
(Table 3). Associations among the high, moderate, and 
low- intensity groups of statin therapy (see “Patients 
and Methods” section) and the effects described 
previously could not be detected either (Supporting 
Tables S1- S3).
Role oF tHe slCo1B1 
tRanspoRteR VaRiant
All patients on statins were genotyped successfully 
for the SLCO1B1 loss- of- function variant p.V174A. 
For 2 patients without statins, genotyping was not 









Body mass index (kg/m2) 216 28.6 ± 5.8
Charlson index 226 5.9 ± 2.2
Etiology of cirrhosis
Alcoholism 144 46.8%
Hepatitis B 7 2.3%





Decompensated stage 193 62.7%
MELD 308 11.9 ± 4.8




LSM (kPa) 167 35.8 ± 21.3
LSPS 167 5.2 ± 9.4
FIB- 4 228 5.1 ± 7.9
Spleen size (cm) 283 13.5 ± 2.8
Total bilirubin (mg/dL) 308 1.5 ± 1.6
Type of statin
Simvastatin 87 63.0% (in statin group)
Atorvastatin 39 28.3% (in statin group)
Pravastatin 8 5.8% (in statin group)
Fluvastatin 4 2.9% (in statin group)
Simvastatin equivalent dose 
(mg/ day)
154 35.2 ± 22.1
Intensity of statin therapy
Low 13 10.5% (in statin group)
Moderate 93 75.0% (in statin group)
High 18 14.5% (in statin group)
Abbreviation: NAFLD, nonalcoholic fatty liver disease.
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possible due to insufficient DNA samples. In this 
cohort, 225 wild type carriers, 76 heterozygous, and 
5 homozygous SLCO1B1 risk allele carriers were 
detected, which is consistent with the Hardy- Weinberg 
equilibrium (P  =  0.813; exact test). Correspondingly, 
the minor allele frequency was 14.1%, similar to the 
frequency of 15.9% in a large European population 
(gnomAD database).(29)
The impact of the variant in SLCO1B1 was ana-
lyzed separately in the statin and control groups 
to delineate the effects of statin therapy. Table 4 
summarizes the results of this analysis. Applying a 
dominant model (wild type vs. heterozygous + 
homozygous carriers) in the statin group, decom-
pensation events, PH, bacterial infections, and total 
bilirubin concentrations all indicate that the bene-
ficial effects of statins are reduced by the presence 
of the SLCO1B1 variant. Although some differences 
nominally did not reach significance, the frequencies 
consistently point in the same direction: Variceal 
bleeding, HE, jaundice, and ascites as clinical signs 
of decompensation (and rate of hepatocellular carci-
noma) are markedly reduced in wild type carriers in 
comparison to patients with loss- of- function alleles, 
taBle 3. Results in psm- matCHeD CoHoRt CompaRing 154 patients WitHout anD 154 patients 
on statins
No Statin Statin P OR 95% CI
Body mass index (kg/m2) 27.9 ± 6.0 29.2 ± 5.5 0.23
Child- Turcotte- Pugh score 7.3 ± 2.2 7.0 ± 2.0 0.41
Charlson index 6.0 ± 2.3 5.8 ± 2.2 0.18
Decompensation 106 (68.8) 87 (56.5) 0.02 0.54 0.32- 0.90
Variceal bleeding 22 (14.3) 9 (5.8) 0.02 0.35 0.15- 0.83
HE 24 (15.6) 21 (13.6) 0.62 0.85 0.45- 1.62
Jaundice 31 (20.1) 29 (18.8) 0.78 0.92 0.53- 1.61
Ascites 92 (59.7) 74 (48.1) 0.04 0.61 0.38- 0.97
HRS 9 (5.8) 4 (2.4) 0.18 0.44 0.14- 1.44
PH
Esophageal varices 95 (62.1) 63 (41.4) <0.001 0.39 0.23- 0.66
LSM (kPa) 36.3 ± 21.1 35.4 ± 21.6 0.29
LSPS 5.6 ± 6.4 4.8 ± 11.5 0.01
FIB- 4 5.4 ± 4.7 4.8 ± 10.1 0.02
Spleen size (cm) 13.8 ± 2.9 13.1 ± 2.5 0.02
Hepatocellular carcinoma 54 (35.1) 43 (27.9) 0.16 0.69 0.42- 1.16
Bacterial infection (yes) 43 (27.9) 46 (29.9) 0.71 1.10 0.67- 1.80
Decompensated (yes) 37 (86.0) 32 (69.6)
Compensated (yes) 6 (14.0) 14 (30.4)
Laboratory parameters
WBC (×109) 6.5 ± 0.8 7.3 ± 3.7 0.03
Platelets (×109) 146 ± 87 182 ± 104 <0.001
ALT (IU/L) 48 ± 67 72 ± 144 0.13
AST (IU/L) 76 ± 117 67 ± 95 0.39
AST (IU/L) 67 ± 95 76 ± 117 0.39
CRP (mg/dL) 19 ± 27 16 ± 27 0.33
LDL (mg/dL) 95 ± 37 91 ± 62 0.40
HDL (mg/dL 41 ± 23 43 ± 23 0.18
Cholesterol (mg/dL) 156 ± 48 151 ± 71 0.37
Triglycerides (mg/dL) 128 ± 95 128 ± 68 0.77
HbA1c (mmol/mol) 43.1 ± 16.9 46.1 ± 16.3 0.17
CK (IU/L) 96 ± 77 112 ± 91 0.03
Events of myopathy 0 3 (1.9) 0.39 65.80
Note: Data is presented as frequency and percentage or means and SD. Significant P values are marked in bold. Decompensated patients 
can have multiple decompensation events.
Abbreviations: CRP, C- reactive protein; HbA1c, hemoglobin A1c; WBC, white blood count.
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taBle 4. analysis oF tHe Dominant moDel oF tHe SLCO1B1 VaRiant p.V174a in patients on 
statins
Wild Type Heterozygous + Homozygous P OR 95% CI
Age (years) 64.9 ± 9.3 66.9 ± 9.8 0.29
Sex (male) 91 (76.5) 24 (68.6) 0.35 1.49 0.65- 3.42
Body mass index (kg/m2) 29.3 ± 5.6 28.7 ± 5.2 0.65
Charlson index 5.7 ± 2.2 6.3 ± 2.2 0.28
MELD 11.3 ± 4.6 13.5 ± 5.8 0.01
Child- Turcotte- Pugh score 6.8 ± 1.9 7.6 ± 2.2 0.19
Simvastatin equivalent dose (mg) 35.8 ± 22.2 32.4 ± 22.1 0.41
Decompensation 63 (52.9) 24 (68.6) 0.10 1.94 0.87- 4.31
Variceal bleeding 5 (4.2) 4 (11.4) 0.11 2.94 0.75- 11.60
HE 13 (10.9) 8 (22.9) 0.07 2.42 0.90- 2.42
Jaundice 20 (16.8) 9 (25.7) 0.24 1.71 0.70- 4.20
Ascites 53 (44.5) 21 (60.0) 0.11 1.87 0.87- 4.02
HRS 1 (0.8) 3 (8.6) 0.01 11.07 1.11- 109.97
PH
Esophageal varices 42 (35.9) 21 (60.0) 0.01 2.68 1.24- 5.81
LSM (kPa) 33.7 ± 21.0 43.0 ± 23.5 0.12
LSPS 4.9 ± 12.6 4.5 ± 4.9 0.35
FIB- 4 4.8 ± 11.3 5.0 ± 3.5 0.08
Spleen size (cm) 13.0 ± 2.5 13.5 ± 2.5 0.14
Hepatocellular carcinoma 29 (24.4) 14 (40.0) 0.07 2.07 0.90- 2.42
Bacterial infection (yes) 30 (25.2) 16 (45.7) 0.02 2.50 1.14- 5.47
Decompensated (yes) 17 (56.6)) 15 (93.8)
Compensated (yes) 13 (43.3) 1 (6.2)
Laboratory parameters
Serum sodium (mmol/L) 139 ± 4 137 ± 5 0.07
Serum creatinine (mg/dL) 1.2 ± 0.7 1.3 ± 0.9 0.47
Urea (g/dL) 46 ± 35 49 ± 43 0.52
Total bilirubin (mg/dL) 1.3 ± 1.7 2.0 ± 2.3 0.007
ALT (IU/L) 75 ± 145 60 ± 139 0.06
AST (IU/L) 72 ± 93 90 ± 175 0. 96
Serum albumin (g/dL) 36 ± 9 35 ± 7 0.12
CRP (mg/dL) 16 ± 27 17 ± 26 0.30
WBC (×109) 7.2 ± 3.9 7.5 ± 3.0 0.31
Hemoglobin (g/dL) 12.8 ± 2.2 11.4 ± 2.6 0.007
Platelets (×109) 189 ± 112 156 ± 74 0.13
INR 1.2 ± 0.4 1.3 ± 0.3 0.02
PTT (seconds) 28.9 ± 5.5 32.2 ± 7.3 0.02
Cholesterol (mg/dl) 152 ± 71 144 ± 72 0.70
LDL cholesterol (mg/dL) 94 ± 66 78 ± 36 0.40
HDL cholesterol (mg/dL) 44 ± 24 37 ± 20 0.36
Triglycerides (mg/dL) 126 ± 67 133 ± 78 0.59
HbA1c (mmol/mol) 46.6 ± 16.6 43.7 ± 14.4 0.36
CK (IU/L) 111 ± 70 114 ± 164 0.04
Note: Data is presented as frequency and percentage or means and SD. Significant P values are marked in bold. Decompensated patients 
can have multiple decompensation events.
Abbreviations: CRP, C- reactive protein; HbA1c, hemoglobin A1c; PTT, partial thromboplastin time; WBC, white blood count.
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whereas HRS occurs significantly more often in 
the latter patients (OR  =  11.07, 95% CI 1.11- 110; 
P  =  0.01). As a major sign of PH, the presence of 
esophageal varices is significantly higher in carriers 
of the variant alleles (OR = 2.68, 95% CI 1.24- 5.81; 
P  =  0.01). Accordingly, the FIB- 4 index and other 
markers (LSM, spleen size) signal less advanced PH 
in patients without the variant (Table 4).
Of note, patients with SLCO1B1 loss- of- function 
alleles are also more likely to present with bacterial 
infections (OR = 2.50, 95% CI 1.14- 5.47; P = 0.02). 
Remarkably, there was an overall increased excretion 
capacity of the liver, as reflected by significantly lower 
total bilirubin concentrations (1.3  ±  1.7  mg/dL vs. 
2.0  ±  2.3  mg/dL; P  =  0.007) and MELD scores in 
patients without risk alleles (11.3 ± 4.6 vs. 13.5 ± 5.8; 
P  =  0.01). Accordingly, lower international normal-
ized ratio (INR; 1.2 ± 0.4 vs. 1.3 ± 0.3; P = 0.02) and 
shorter partial thromboplastin time (28.9  ±  5.5  vs. 
32.2  ±  7.3  seconds; P  =  0.02) indicate higher liver 
synthesis capacity. Serum sodium, ALT, and platelets 
showed consistent trends to levels indicating amelio-
rated hepatic injury (Table 4). In contrast, carriage of 
the risk allele was found to confer increased CK activ-
ities (114 ± 164  IU/L vs. 111 ± 70  IU/L; P  = 0.04). 
Due to a low number of homozygous patients, the 
recessive model is not expressive, however, it is com-
parable to the described results (Supporting Table S5).
In the control group of patients not taking statins, 
the presence of the variant p.V174A did not have any 
consistent impact on the outcome of patients with cir-
rhosis (Supporting Table S4). The results in the dom-
inant model were inconsistent: HRS was more likely 
in wild type carriers (OR = 0.68, 95% CI 0.61- 0.76; 
P = 0.04), and AST levels were lower in these patients 
(74  ±  103  IU/L vs. 51  ±  47  IU/L; P  =  0.04). Other 
variables did not show corresponding trends. In con-
trast, in the recessive model, no consistent effects were 
observed (Supporting Table S6).
Discussion
Portal hypertension is a common consequence of 
cirrhosis, caused by the increase of the intrahepatic 
resistance due to destruction of the parenchyma of the 
liver, accumulation of extracellular matrix, and systemic 
arterial vasodilation. The ideal treatment of PH would 
be drugs that reduce hepatic resistance without affecting 
hepatic perfusion and display anti- inflammatory as 
well as antifibrotic effects.(31) Statins— in addition to 
their lipid- lowering effects— decrease hepatic resis-
tance and increase hepatic blood flow and, and in con-
trast to β- blockers, do not negatively affect systemic 
hemodynamics in cirrhosis.(32) Therefore, as warranted 
by experimental data, the impact of statins was inves-
tigated in randomized trials and observational stud-
ies,(3,5,7,9,33,34) which indicated reduction of portal 
pressure and lower rates of infections in cirrhosis.
In this study, we investigated the effect of sta-
tin treatment in patients with cirrhosis by minimiz-
ing confounding factors such as stage of disease and 
degree of PH. Previous studies examined the statin 
effects on portal pressure using invasive measure-
ments.(3,5) In this context, we analyzed whether these 
observations are reflected by noninvasive assessment 
of PH. Spleen size, the presence of esophageal varices, 
platelet counts, and FIB- 4 indexes were reduced in 
patients on statins in the matched cohort, indicating 
decreased PH. These results could also be confirmed 
by elastography and calculating LSPS, as expressed 
by the reduction of the single components (liver stiff-
ness, platelets, spleen size) as well as the full score. 
Consecutively, PH- associated events of decompensa-
tion such as ascites and variceal bleeding occurred less 
frequently in patients taking statins. Serum lipid con-
centrations did not differ between treated and non-
treated patients, indicating that the overall prescribed 
statin doses are effective.
After confirming the previously described data, we 
specifically studied the effects of the SLCO1B1 loss- of- 
function variant p.V174A (c.521T>C), which leads to 
a reduced hepatic uptake of statins.(17) We availed of 
a large cohort of patients with genetic information on 
p.V174A to establish the PSM cohort of patients with 
cirrhosis. This analysis revealed consistent differences 
between wild type and risk allele carriers in the group 
of patients with cirrhosis who took statins: Patients 
carrying the risk allele developed more complications 
of cirrhosis associated to PH. Notably, we found more 
bacterial infections in patients carrying the SLCO1B1 
risk variant. There are scarce data in patients with cir-
rhosis, but other studies described less frequent pulmo-
nary infections,(35) sepsis,(36) as well as reduced overall 
mortality(37) because of lower frequency of infections in 
patients on statins. Taken together, our findings indicate 
that the SLCO1B1 variant could lead to reduced ther-
apeutic efficacy of statins in patients with cirrhosis. As 
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the same analysis in the control group did not reveal 
consistent associations, we suggest that in this cohort 
the genotype itself does not impact the clinical course 
of cirrhosis. Therefore, we suggest that the beneficial 
effects of statins in patients with cirrhosis might be lim-
ited in patients carrying the p.V174A risk allele. Even 
though we did not conduct functional analyses, we 
speculate that the higher frequency of bacterial infec-
tions and increased PH in patients with the SLCO1B1 
risk allele taking statins could be a consequence of the 
reduced intrahepatic effect of statins.
Statins are prescribed with caution in patients with 
chronic liver diseases due to the fear of side effects, 
and there is reluctance of many physicians to prescribe 
statins in patients with cirrhosis. In fact, pharmacoki-
netics of statins, as assessed by maximum concentration 
and area under the curve, are altered and SLCO1B1 
expression is decreased in patients with cirrhosis.(38) 
Of note, in our patients the levels of liver enzymes and 
bilirubin did not differ between statin users and nonus-
ers. Additionally, no case of statin- induced liver injury 
was noted in any of our patients. Hence, our findings, 
together with the known cardiovascular and potential 
hepatic benefits, provide further support for the care-
ful use of statins in this vulnerable population. This is 
in line with small prospective and larger retrospective 
studies that found statins to be safe in compensated cir-
rhosis.(39) Further studies are currently being performed 
assessing the safety and efficacy of different doses of 
statins in patients with decompensated cirrhosis.(40) In 
fact, we could not exactly determine the defined daily 
doses, and information on type or dose was not avail-
able in a subgroup of our patients. Most of the patients 
were treated with the lipophilic compound simvastatin; 
therefore, other types of more hydrophilic statins are 
less represented. Even though statins express a class 
effect, we could not assess pleiotropic mechanisms on 
liver and intestine or metabolic pathways either.
Our study design has certain limitations that are 
mostly inherent to the retrospective design. In our 
PSM model, we could have potentially missed addi-
tional confounders of statin therapy, and we might have 
created distortion because of the selection of variables. 
Due to the lack of data, we could not balance the dura-
tion, indication, or decision to initiate therapy (e.g., 
HDL, LDL), and accordingly we could not address 
the indication bias of statin therapy, which might also 
resemble the fact that patients with a more advanced 
stage of the disease might be prescribed statins less 
commonly. Therefore, we could not provide information 
on the dose or duration of statin treatment required for 
the effects. Because the overall size of our PSM cohort 
was moderate, some confidence intervals were wide, 
and we therefore might have missed small effects. We 
could robustly assess the dominant association model 
only. The study design was retrospective and observa-
tional, so we could not perform an analysis of survival 
or decompensation- free time. Our findings should be 
therefore confirmed in prospective controlled studies. 
To quantify the pharmacological associations, other 
study designs are required. Due to the cross- sectional 
study design, no assessment of causality can be made. 
Because the exposure periods of statin therapy might 
be missed in a few patients, events or bacterial infec-
tions could occur outside the exposure period in a small 
number of patients. Notwithstanding the potential bias 
of observational analyses on statins,(38) in our study the 
results after genetic stratification fully support the ben-
eficial effects of statins on cirrhosis outcomes.
In summary, we assessed the effect of a loss- 
of- function variant in SLCO1B1, causing reduced 
hepatic uptake of statins on markers and signs of PH 
in a retrospectively propensity score– matched cohort 
of patients with cirrhosis. We found that signs of 
PH were reduced in patients with cirrhosis on sta-
tin therapy. Notably, carriers of the common loss- of- 
function SLCO1B1 variant appeared to benefit less 
from statin therapy and developed more bacterial 
infections, increased PH, and associated compli-
cations. Future molecular studies and prospective 
assessment of genetic testing for SLCO1B1 variants 
in patients with cirrhosis and PH are now warranted.
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